Due to dedifferentiation of tumor cells, patients have reduced expression and abnormal function of thyroid-stimulating hormone receptor (TSHR) and natrium iodide symporter (NIS), resulting in insensitivity to 131I therapy and thus becoming iodine-refractory differentiated thyroid cancer with poor prognosis. Here, TSHR is linked to neoplasm.